<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100868">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01955759</url>
  </required_header>
  <id_info>
    <org_study_id>0115/09 - (2013)</org_study_id>
    <nct_id>NCT01955759</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation and By-pass Surgery</brief_title>
  <official_title>Pharmacologic Prophylaxis for Atrial Fibrillation Following Coronary By-Pass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Center BH Tuzla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart Center BH Tuzla</source>
  <oversight_info>
    <authority>Bosnia and Herzegovina: Federal Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate whether combined therapy with beta-blocker, amiodarone
      and statine is better than beta-blocker alone for the prevention of atrial fibrillation
      after coronary by-pass surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>atrial fibrillation</measure>
    <time_frame>10 days on average during hospital stay after coronary by-pass surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>outcome will be number of patients free from atrial fibrillation.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Patients With Coronary Artery Disease Scheduled for by Pass Surgery</condition>
  <arm_group>
    <arm_group_label>beta blocker and amiodarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>beta blocker and statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>beta blocker</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive beta blocker (Bisoprolol tab in adjusted dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone  tab 200 mg x 3</intervention_name>
    <description>starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge</description>
    <arm_group_label>beta blocker and amiodarone</arm_group_label>
    <other_name>cordarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin 20 mg tab x1</intervention_name>
    <description>starting 7 days before coronary by-pass surgery</description>
    <arm_group_label>beta blocker and statin</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta blockers Bisoprolol in adjusted dose</intervention_name>
    <description>starting 7 days befoe coronary by-pass surgery</description>
    <arm_group_label>beta blocker and amiodarone</arm_group_label>
    <arm_group_label>beta blocker and statin</arm_group_label>
    <arm_group_label>beta blocker</arm_group_label>
    <other_name>zebeta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  significant coronary disease, sinus rhythm

        Exclusion Criteria:

          -  valvular disease, former by-pass surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enes Osmanovic, Master's degree</last_name>
    <phone>+387 66 725 744</phone>
    <email>osmanovic@bhsrce.ba</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Goran Imamovic</last_name>
    <email>goran.imamovic@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center BH</name>
      <address>
        <city>Tuzla</city>
        <state>TK</state>
        <zip>75000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enes Osmanović</last_name>
      <phone>+387 66 725 744</phone>
      <email>osmanovic@bih.net.ba</email>
    </contact>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 15, 2013</lastchanged_date>
  <firstreceived_date>September 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heart Center BH Tuzla</investigator_affiliation>
    <investigator_full_name>Enes Osmanović</investigator_full_name>
    <investigator_title>Mr.med.sc.Dr Enes Osmanovic</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
